SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1538 3598 OR L773:0098 7484 "

Sökning: L773:1538 3598 OR L773:0098 7484

  • Resultat 291-300 av 340
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
291.
  • Jacobsen, Juliet, et al. (författare)
  • Shifting to Serious Illness Communication
  • 2022
  • Ingår i: JAMA - Journal of the American Medical Association. - : American Medical Association (AMA). - 0098-7484. ; 327:4, s. 321-322
  • Tidskriftsartikel (refereegranskat)
  •  
292.
  • Johansson, JE, et al. (författare)
  • Fifteen-year survival in prostate cancer - A prospective, population-based study in Sweden
  • 1997
  • Ingår i: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. - : AMER MEDICAL ASSOC. - 0098-7484. ; 277:6, s. 467-471
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective.-To describe the natural history of initially untreated early-stage prostate cancer. A key secondary objective was to calculate long-term survival rates by stage, grade, and age at diagnosis. Design.-Prospective cohort study, Setting.-Population
  •  
293.
  •  
294.
  •  
295.
  •  
296.
  •  
297.
  • Konstam, M. A., et al. (författare)
  • Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial
  • 2007
  • Ingår i: JAMA. - 1538-3598. ; 297:12, s. 1319-31
  • Tidskriftsartikel (refereegranskat)abstract
    • CONTEXT: Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure. OBJECTIVE: To investigate the effects of tolvaptan initiated in patients hospitalized with heart failure. DESIGN, SETTING, AND PARTICIPANTS: The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST), an event-driven, randomized, double-blind, placebo-controlled study. The outcome trial comprised 4133 patients within 2 short-term clinical status studies, who were hospitalized with heart failure, randomized at 359 North American, South American, and European sites between October 7, 2003, and February 3, 2006, and followed up during long-term treatment. INTERVENTION: Within 48 hours of admission, patients were randomly assigned to receive oral tolvaptan, 30 mg once per day (n = 2072), or placebo (n = 2061) for a minimum of 60 days, in addition to standard therapy. MAIN OUTCOME MEASURES: Dual primary end points were all-cause mortality (superiority and noninferiority) and cardiovascular death or hospitalization for heart failure (superiority only). Secondary end points included changes in dyspnea, body weight, and edema. RESULTS: During a median follow-up of 9.9 months, 537 patients (25.9%) in the tolvaptan group and 543 (26.3%) in the placebo group died (hazard ratio, 0.98; 95% confidence interval [CI], 0.87-1.11; P = .68). The upper confidence limit for the mortality difference was within the prespecified noninferiority margin of 1.25 (P<.001). The composite of cardiovascular death or hospitalization for heart failure occurred in 871 tolvaptan group patients (42.0%) and 829 placebo group patients (40.2%; hazard ratio, 1.04; 95% CI, 0.95-1.14; P = .55). Secondary end points of cardiovascular mortality, cardiovascular death or hospitalization, and worsening heart failure were also not different. Tolvaptan significantly improved secondary end points of day 1 patient-assessed dyspnea, day 1 body weight, and day 7 edema. In patients with hyponatremia, serum sodium levels significantly increased. The Kansas City Cardiomyopathy Questionnaire overall summary score was not improved at outpatient week 1, but body weight and serum sodium effects persisted long after discharge. Tolvaptan caused increased thirst and dry mouth, but frequencies of major adverse events were similar in the 2 groups. CONCLUSION: Tolvaptan initiated for acute treatment of patients hospitalized with heart failure had no effect on long-term mortality or heart failure-related morbidity. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00071331
  •  
298.
  • Kuchenbaecker, Karoline B., et al. (författare)
  • Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
  • 2017
  • Ingår i: JAMA - Journal of the American Medical Association. - : American Medical Association (AMA). - 0098-7484. ; 317:23, s. 2402-2416
  • Tidskriftsartikel (refereegranskat)abstract
    • IMPORTANCE The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospective cancer risk estimates. OBJECTIVES To estimate age-specific risks of breast, ovarian, and contralateral breast cancer for mutation carriers and to evaluate risk modification by family cancer history and mutation location. DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study of 6036 BRCA1 and 3820 BRCA2 female carriers (5046 unaffected and 4810 with breast or ovarian cancer or both at baseline) recruited in 1997-2011 through the International BRCA1/2 Carrier Cohort Study, the Breast Cancer Family Registry and the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, with ascertainment through family clinics (94%) and population-based studies (6%). The majority were from large national studies in the United Kingdom (EMBRACE), the Netherlands (HEBON), and France (GENEPSO). Follow-up ended December 2013; median follow-up was 5 years. EXPOSURES BRCA1/2 mutations, family cancer history, and mutation location. MAIN OUTCOMES AND MEASURES Annual incidences, standardized incidence ratios, and cumulative risks of breast, ovarian, and contralateral breast cancer. RESULTS Among 3886 women (median age, 38 years; interquartile range [IQR], 30-46 years) eligible for the breast cancer analysis, 5066 women (median age, 38 years; IQR, 31-47 years) eligible for the ovarian cancer analysis, and 2213 women (median age, 47 years; IQR, 40-55 years) eligible for the contralateral breast cancer analysis, 426 were diagnosed with breast cancer, 109 with ovarian cancer, and 245 with contralateral breast cancer during follow-up. The cumulative breast cancer risk to age 80 years was 72%(95%CI, 65%-79%) for BRCA1 and 69%(95%CI, 61%-77%) for BRCA2 carriers. Breast cancer incidences increased rapidly in early adulthood until ages 30 to 40 years for BRCA1 and until ages 40 to 50 years for BRCA2 carriers, then remained at a similar, constant incidence (20-30 per 1000 person-years) until age 80 years. The cumulative ovarian cancer risk to age 80 years was 44%(95%CI, 36%-53%) for BRCA1 and 17%(95%CI, 11%-25%) for BRCA2 carriers. For contralateral breast cancer, the cumulative risk 20 years after breast cancer diagnosis was 40% (95%CI, 35%-45%) for BRCA1 and 26%(95%CI, 20%-33%) for BRCA2 carriers (hazard ratio [HR] for comparing BRCA2 vs BRCA1, 0.62; 95%CI, 0.47-0.82; P=.001 for difference). Breast cancer risk increased with increasing number of first- and second-degree relatives diagnosed as having breast cancer for both BRCA1 (HR for 2 vs 0 affected relatives, 1.99; 95%CI, 1.41-2.82; P<.001 for trend) and BRCA2 carriers (HR, 1.91; 95%CI, 1.08-3.37; P=.02 for trend). Breast cancer risk was higher if mutations were located outside vs within the regions bounded by positions c.2282-c.4071 in BRCA1 (HR, 1.46; 95%CI, 1.11-1.93; P=.007) and c.2831-c.6401 in BRCA2 (HR, 1.93; 95%CI, 1.36-2.74; P<.001). CONCLUSIONS AND RELEVANCE These findings provide estimates of cancer risk based on BRCA1 and BRCA2 mutation carrier status using prospective data collection and demonstrate the potential importance of family history and mutation location in risk assessment.
  •  
299.
  •  
300.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 291-300 av 340
Typ av publikation
tidskriftsartikel (331)
forskningsöversikt (6)
annan publikation (2)
konferensbidrag (1)
Typ av innehåll
refereegranskat (272)
övrigt vetenskapligt/konstnärligt (68)
Författare/redaktör
Stephansson, O (12)
Lind, Lars (7)
Rosengren, Annika, 1 ... (7)
Cnattingius, S (7)
Sundström, Johan (7)
Hedblad, Bo (6)
visa fler...
Larsson, Henrik, 197 ... (6)
Lichtenstein, Paul (6)
Ingelsson, Erik (6)
Wallentin, Lars (6)
Norman, M. (5)
Lund, LH (5)
Adami, HO (5)
Wolk, A (5)
Wolk, Alicja (5)
Neovius, M (5)
Johansson, S (5)
Edgren, G (5)
Hansson, Oskar (5)
Olsson, Anders (5)
Wedel, Hans (5)
Psaty, B. M. (5)
Jernberg, Tomas (5)
Ärnlöv, Johan (5)
Pasternak, B (5)
Barrett-Connor, E. (5)
Engström, Gunnar (4)
Larsson, Anders (4)
Khaw, K. T. (4)
Lagergren, J (4)
Swedberg, Karl, 1944 (4)
Yusuf, S. (4)
Melander, Olle (4)
Ekbom, A (4)
Gudnason, V (4)
Larsson, Susanna C. (4)
Dahlström, Ulf (4)
Fox, Keith A. A. (4)
Melhus, Håkan (4)
Sandin, S (4)
Danesh, J (4)
Di Angelantonio, E (4)
Hofman, Albert (4)
Hjalgrim, H (4)
Wedel, H. (4)
Thompson, S. G. (4)
Kaptoge, S. (4)
Woodward, M (4)
Salonen, J. T. (4)
Thompson, Simon G. (4)
visa färre...
Lärosäte
Karolinska Institutet (188)
Uppsala universitet (83)
Lunds universitet (62)
Göteborgs universitet (52)
Linköpings universitet (30)
Umeå universitet (24)
visa fler...
Örebro universitet (18)
Stockholms universitet (4)
Högskolan Dalarna (4)
Högskolan i Borås (3)
Mälardalens universitet (2)
Malmö universitet (2)
Blekinge Tekniska Högskola (2)
Röda Korsets Högskola (2)
Kungliga Tekniska Högskolan (1)
Jönköping University (1)
Högskolan i Skövde (1)
Gymnastik- och idrottshögskolan (1)
visa färre...
Språk
Engelska (338)
Svenska (1)
Odefinierat språk (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (160)
Samhällsvetenskap (3)
Naturvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy